Overview
Blue Industries provides health diagnostics and genetic analysis for individuals and corporate clients, using genetic data to predict future health risks and offering COVID-19 severe disease risk testing. Its platform combines bioinformatics and material science to deliver online diagnostic services that generate actionable health insights, sold to customers through service fees. The company differentiates itself with a strong focus on data security, regulatory compliance, and an online-first delivery model that serves both individuals and businesses. Its goal is to offer practical, predictive health diagnostics while protecting personal data and meeting legal standards.
Work here?Claim your company
Simplify's take
What believers are saying
- October 30, 2026 VerticallimIT partnership adds a new distribution channel for bluedrop.
- GeneQuest's existing management stayed on, reducing immediate acquisition disruption.
- Blue now combines inherited-risk testing with current-risk diagnostics, increasing cross-sell opportunities.
What critics are saying
- GeneQuest integration after August 2026 creates privacy, board, and culture failure risk.
- bluedrop's cancer-risk claims face regulatory and scientific scrutiny if results disappoint clinics.
- If users distrust predictive genetics, Blue's core consumer funnel collapses within 2027.
What makes Blue Industries unique
- Blue Industries pairs bluedrop urine microRNA cancer screening with GeneQuest's 360-trait genetics.
- August 1, 2026 GeneQuest acquisition gives Blue a consumer genomics data moat.
- Blue sells online diagnostics directly to consumers and corporations, avoiding hospital channel dependence.
Help us improve and share your feedback! Did you find this helpful?